Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Zydus Lifesciences Limited Press Release Jan 07 2025

· Issued by Zydus Lifesciences Limited via NSE India

Filed with NSE · · 3 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has announced a press release regarding an agreement with CVS Caremark. The products are indicated for improving glycemic control in adults with type two diabetes mellitus. The press release emphasizes Zydus' commitment to enhancing access to high-quality medications for patients.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated January 07, 2025, titled "Zydus announces agreement with CVS Caremark to add Zituvio TM, Zituvimet TM and Zituvimet TM XR (Sitagliptin Sitagliptin and Metformin Hydrochloride) to its template formulary".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases